Meet us at BIO Europe Spring 2021

Meet Sciomics at Bio Europe Spring - Focus: COVDI-19 Disease Severity Biomarkers

> english version Imprint

 

Impressum

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Telefon: +49 6221 4294830
Telefax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH wird vertreten durch: Geschäftsführer Dr. Christoph Schröder

 

Registergericht: Amtsgericht Mannheim
Handelsregister
Registernummer: HRB716969

Umsatzsteuer-Identifikationsnummer gemäß § 27a Umsatzsteuergesetz: DE289272460

 

Urheberrecht

Alle Inhalte der Internetpräsenz der Sciomics GmbH sind urheberrechtlich geschützt. Dies gilt für Texte wie auch Fotos, Grafiken sowie PDF-Dokumente.
Jede Vervielfältigung oder Verbreitung dieses Internetangebotes oder auch von Inhalten, Auszügen, Dateien oder anderen Teilen davon, zum Beispiel zum Nachdruck, zur Kopie in andere Internetseiten oder zur Weitergabe in elektronischer Form, bedarf der schriftlichen Genehmigung der Sciomics GmbH.

 

Haftung

Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

 

 

 

Imprint

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Phone: +49 6221 4294830
Fax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH is represented by: Geschäftsführer Dr. Christoph Schröder

 

Register jurisdiction: Amtsgericht Mannheim
Commercial Register
Registration number: HRB716969

Umsatzsteuer-Identifikationsnummer (VAT identification number) according to §27a of the Umsatzsteuergesetz (UStG, Sales Tax Law): DE289272460

 

Copyright

The layout, texts, text fragments and graphics used and any other contents on the homepage protected by copyright law. All rights reserved.

 

Liability

Links have been proved during setup. Since information on the WWW is subject of current change Sciomics accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.
This disclaimer is not intended to contravene any requirements laid down in applicable national law nor to exclude liability for matters which may not be excluded under that law.


 

 

 

 

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

Testimonials

"The quality of the data we have obtained is exceptional."

 

Prof. Claudio Mauro
Birmingham University, Institute of Inflammation and Ageing, Birmingham, UK

"We have performed an acetylation array on primary T lymphocytes with Sciomics. The quality of the data we have obtained is exceptional. They have a model of collaboration with the team conducting the experiment. This means they generate the data and assist with further analyses of the data. The screening has opened up several exciting ways forward for us."

Product: scioAcetyl protein and protein acetylation profiling service (under co-development with selected partners)

 

Tweets